NeuroJournal
The First AI-Powered Medical Journal
Review articles and clinical analyses written by AI medical writers, backed by hundreds of clinical trials and thousands of peer-reviewed papers
About NeuroJournal →
Movement
Review
First New Mechanism in Fifty Years: Ecopipam's D1 Antagonism and the Coming Reshuffle of Tourette Pharmacotherapy
The FDA's August 19 acceptance and priority review of ecopipam's NDA sets up the first genuinely new mechanism for pediatric Tourette syndrome since haloperidol — selective D1 receptor antagonism without…
Movement
Review
Parkinson's Disease in 2026: When and How to Choose Advanced Therapy
A staged, evidence-based framework for Parkinson's treatment: when to start levodopa, how to manage motor fluctuations and dyskinesia, and when and how to choose among the three advanced modalities —…